Last updated 2026-07-30
TL;DR
There's no established lethal or toxic dose of enclomiphene in humans, and no published case reports of fatal overdose. Clinical trials safely tested doses up to 25mg/day. The realistic risks are visual disturbances, mood changes, and blood clot risk at high or prolonged doses, not acute organ failure. Compounding means dosing accuracy varies by pharmacy, which is the actual safety weak point.
What happens if you take too much enclomiphene?
Nobody has published a documented case of enclomiphene overdose death or acute organ failure in a human. That's the honest starting point. Enclomiphene is the trans-isomer of clomiphene citrate, and it's been studied in formal Phase 2 and Phase 3 trials (the Androxal program, run by Repros Therapeutics) at doses ranging from 6.25mg up to 25mg per day for months at a stretch [1]. Nobody in those trials died or landed in the ICU from the drug itself. That doesn't mean overdose is harmless. It means the toxicity profile looks more like "unpleasant and hormonally disruptive" than "immediately dangerous," based on what's been published. If you take way more than prescribed, the most likely outcomes are exaggerated versions of normal side effects: visual disturbances, mood swings, headache, and an overshoot in LH and FSH that pushes testosterone and estradiol higher than intended. In rare cases, a testosterone and estradiol spike can worsen mood instability or increase clotting risk, particularly in someone with an undiagnosed clotting disorder. The real-world overdose scenario almost nobody talks about: swallowing a whole month's supply at once because the bottle wasn't labeled clearly, or a compounding error that puts more active drug in each capsule than intended. That's a sourcing and quality-control problem, not a pharmacology problem, and it's one reason providers care about which pharmacy fills the prescription.
Is there a known lethal dose of enclomiphene?
No LD50 or established lethal dose has been published for enclomiphene in humans, and no death from enclomiphene overdose appears in the medical literature indexed by PubMed as of this writing. This is a meaningful evidence gap, not a guarantee of safety at any dose. What we do have: clomiphene citrate (the mixture of enclomiphene and its isomer zuclomiphene) has decades of use in infertility medicine at doses of 50 to 150mg/day for ovulation induction, and serious acute toxicity from clomiphene overdose is not a common feature of that literature either [2]. The FDA label for clomiphene citrate lists overdose experience as limited, describing nausea, vomiting, hot flashes, visual symptoms, and in some cases exaggeration of side effects, without describing a lethal threshold [3]. Enclomiphene itself was never approved by the FDA as a standalone drug. Repros Therapeutics pursued approval under the brand name Androxal for secondary hypogonadism, completed Phase 3 trials, but the program did not reach FDA approval and was discontinued [1]. That means there's no FDA-approved prescribing information, no official overdose section, and no boxed warning to reference. Everything prescribed today is compounded, filled by a compounding pharmacy under a physician's prescription, not manufactured as an FDA-approved commercial product.
What are the symptoms of enclomiphene toxicity or overdose?
Based on the pharmacology of enclomiphene and the overdose experience documented for clomiphene citrate, expect an intensified version of normal side effects rather than a distinct toxic syndrome. Common symptoms reported at therapeutic doses in trials, which would be expected to intensify at supratherapeutic doses, include: hot flashes, headache, mood changes (irritability, anxiety), acne, and visual disturbances such as blurring, floaters, or light sensitivity [1]. Clomiphene's FDA label specifically flags visual symptoms including blurred vision, scotomata (blind spots), and photophobia, and recommends discontinuing the drug if visual symptoms appear [3]. At higher doses, the concern shifts toward: exaggerated estradiol elevation (since more LH-driven testosterone gets aromatized), enlarged ovaries in women (not relevant to the male TRT-alternative use case but documented in the female infertility literature), and a theoretical increase in venous thromboembolism risk, since estrogen modulation can affect clotting factors. None of this rises to acute lethal toxicity in the published record, but visual changes are the one symptom worth treating as a real stop-and-call-your-doctor signal, not something to push through.
How does enclomiphene overdose risk compare to TRT or clomiphene?
| Enclomiphene (compounded) | Not established | Visual symptoms, mood, estradiol overshoot | Tends to preserve sperm production and testicular size | |
|---|---|---|---|---|
| Clomiphene citrate (FDA-approved) | Not established; limited overdose case data [3] | Visual symptoms, ovarian effects, nausea | Also LH/FSH-driven; contains zuclomiphene, a less-studied isomer with a longer half-life | |
| Injectable testosterone (TRT) | Not typically framed as overdose-lethal, but supraphysiologic dosing raises hematocrit, cardiovascular risk | Erythrocytosis (thick blood), sleep apnea worsening, cardiovascular events with chronic supraphysiologic use | Suppresses LH/FSH, shrinks testicles, suppresses sperm count, often to azoospermia | The fertility line is the whole reason enclomiphene exists as a TRT alternative. Exogenous testosterone tells the hypothalamus and pituitary to shut down GnRH and LH/FSH output, since the brain sees plenty of testosterone already circulating and stops signaling the testes to make more. That's why long-term TRT users often see shrinking testicles and low or zero sperm counts. Enclomiphene works upstream: it blocks estrogen receptors in the hypothalamus, which the brain reads as "estrogen is low," so it increases GnRH pulses, which raises LH and FSH, which drives the testes to make more of their own testosterone [4]. Sperm production, which depends on that same LH/FSH signal, isn't shut off the way it is on exogenous T. That mechanism is well-established, but claiming enclomiphene "preserves fertility" as a guaranteed outcome overstates the evidence. Trials show maintained or increased LH, FSH, and total testosterone versus baseline [1], and multiple studies of clomiphene therapy in men report preserved or improved semen parameters, but semen quality and live birth outcomes are not the same endpoint, and long-term reproductive outcome data specific to enclomiphene is thin. For a fuller look at what the studies actually measured, see enclomiphene results timeline and enclomiphene success rate. |
This is the comparison most men actually want, because they're choosing between enclomiphene, testosterone therapy, and clomiphene citrate, and overdose risk is one input into that decision. | Drug | Established lethal dose in humans | Main overdose concern | Fertility impact at normal dose |
What should you do if you suspect an enclomiphene overdose?
Call Poison Control at 1-800-222-1222 (U.S.) or go to an emergency room if someone has taken significantly more enclomiphene than prescribed, especially if they have vision changes, severe headache, chest pain, leg swelling, or shortness of breath. Bring the pill bottle or compounding pharmacy label with you. There's no specific antidote for enclomiphene or clomiphene overdose. Treatment is supportive: managing symptoms as they appear, monitoring vital signs, and watching for signs of thromboembolism if the dose was extreme or prolonged. Because no formal lethal dose exists in the literature, emergency clinicians will treat based on symptoms rather than a known toxic threshold, which is exactly why accurate reporting of how much was taken and over what timeframe matters. If the "overdose" was actually a dosing error, like taking a double dose once because of a missed day, that's a different and much lower-risk situation than intentionally taking a week's supply at once. Most single missed-then-doubled doses in the enclomiphene dose range (12.5mg to 25mg/day in trials [1]) are unlikely to cause serious harm, but you should still call your prescribing provider to report it and get individualized guidance rather than guessing.
What's a safe and typical enclomiphene dose?
Clinical trials for Androxal tested 6.25mg, 12.5mg, and 25mg daily doses in hypogonadal men, with 12.5mg and 25mg being the doses that moved into Phase 3 [1]. Most compounding pharmacies today fill prescriptions in the 12.5mg to 25mg/day range, often starting at 12.5mg and adjusting based on follow-up labs. Because enclomiphene isn't FDA-approved as a standalone drug, there's no official package insert dosing table the way there is for testosterone gel or clomiphene citrate. Dosing is set by the prescribing physician based on trial data, off-label clomiphene experience, and the patient's labs (total testosterone, LH, FSH, estradiol) at baseline and on follow-up. This is a real difference from an FDA-approved drug: dosing guidance comes from clinical judgment and published trial data, not a standardized label. Going above 25mg/day isn't something the trial data supports, and there's no evidence it produces better results, only a higher chance of side effects. More is not better here. If a provider is prescribing daily doses well outside the studied range without a clear reason tied to your labs, that's worth a direct question.
Can enclomiphene cause liver, kidney, or heart damage?
There's no strong signal in the published trial data for direct liver or kidney toxicity from enclomiphene at studied doses. Trials tracked standard safety labs, and the drug's mechanism (estrogen receptor modulation at the hypothalamus) doesn't route through the liver or kidneys the way some hepatotoxic drugs do. The cardiovascular question is more nuanced. Raising testosterone through any mechanism, including enclomiphene, raises hematocrit somewhat, since testosterone stimulates red blood cell production. This is a known, monitorable effect, not unique to enclomiphene, and it's part of why routine bloodwork (CBC, hematocrit, lipids) is standard practice on any testosterone-raising therapy. Clomiphene's label separately notes that estrogen-modulating drugs carry a class-level association with venous thromboembolism risk in some patients [3], which is why anyone with a personal or family history of blood clots should flag that clearly before starting. None of this amounts to established organ toxicity at a specific overdose threshold. It amounts to "get your labs checked periodically," which is unglamorous but is the actual risk-management tool here, not a poison-control hotline.
Why is enclomiphene not FDA-approved, and does that affect overdose risk?
Enclomiphene, marketed as Androxal by Repros Therapeutics, completed Phase 3 trials for secondary hypogonadism in men but never received FDA approval, and the company discontinued the program [1]. This means every enclomiphene prescription filled today comes from a compounding pharmacy, made under a physician's prescription rather than as a mass-manufactured, FDA-approved drug with a standardized label. That has real overdose-risk implications, separate from the drug's own pharmacology. Compounded medications aren't subject to the same batch-testing and bioequivalence requirements as FDA-approved drugs. The FDA states plainly that "compounded drugs are not FDA-approved," and that the agency "does not verify the safety, or effectiveness, of compounded drugs" [5]. That doesn't mean compounded enclomiphene is unsafe, most reputable compounding pharmacies operate under state board of pharmacy oversight and, for larger-scale operations, FDA-registered 503B facility standards, but it does mean the dosing-accuracy safety net that exists for a commercial pill (identical mg content, batch after batch) isn't guaranteed the same way. Practically, this means the pharmacy matters. A prescription filled through a provider who works with a quality-vetted compounding pharmacy is a meaningfully different risk profile than a capsule bought from an unverified online seller with no prescription at all. Enclomiphene Direct's model addresses this by connecting patients with providers who review labs and prescribe through an established compounding pharmacy partner, rather than shipping product with no medical oversight.
How is enclomiphene different from clomiphene, and does that change the risk?
Clomiphene citrate is actually a 50/50 (roughly) mixture of two isomers: enclomiphene (the trans-isomer) and zuclomiphene (the cis-isomer) [4]. When your doctor prescribes "clomid" or generic clomiphene citrate, you're getting both molecules. Enclomiphene, as sold today, is the isolated trans-isomer alone. Why does this matter for toxicity? Zuclomiphene has a much longer half-life than enclomiphene and behaves more like a weak estrogen agonist in some tissues, accumulating over repeated dosing cycles [4]. Enclomiphene is believed to carry most of the anti-estrogenic, LH/FSH-stimulating activity that raises testosterone, while zuclomiphene is the isomer researchers suspect contributes more to estrogen-related side effects like mood changes and possibly the (unconfirmed) concerns about long-term zuclomiphene accumulation. This is the theoretical rationale for isolating enclomiphene: same therapeutic mechanism, potentially fewer of the zuclomiphene-linked side effects. In terms of acute overdose risk specifically, there isn't head-to-head human toxicity data comparing an enclomiphene overdose to a clomiphene overdose at matched doses. The theoretical argument for enclomiphene being "cleaner" is reasonable pharmacology, not a proven toxicity advantage backed by outcome studies. Be honest with yourself about that distinction if a seller frames enclomiphene as risk-free by comparison.
Who should avoid enclomiphene, or use extra caution?
A few groups carry higher baseline risk and deserve a direct conversation with a prescriber before starting, overdose risk aside. Men with a personal or family history of venous thromboembolism (blood clots, pulmonary embolism) should flag this clearly, given the class-level clotting association noted on clomiphene's FDA label [3]. Men with pre-existing liver disease, since the drug is metabolized hepatically even though direct hepatotoxicity hasn't been a strong trial signal. Men with a history of pituitary or hypothalamic tumors, since enclomiphene works by amplifying a hormonal feedback loop that a tumor might already be disrupting. Anyone with unexplained visual field changes or a history of eye disease, given the visual-symptom signal seen with the clomiphene/enclomiphene drug class [3]. And bluntly: anyone sourcing enclomiphene without any physician involvement or lab monitoring is taking on risk that has nothing to do with the molecule itself and everything to do with not knowing your own baseline hormone levels, dose accuracy, or whether the product is what the label claims. That's the most common real-world path to an adverse outcome, not the drug's inherent toxicity ceiling.
What does responsible use of enclomiphene actually look like?
Baseline labs before starting: total and free testosterone, LH, FSH, estradiol, CBC/hematocrit, and a lipid panel. Follow-up labs at roughly 6 to 12 weeks to see how your body responded and to catch an overshoot early, before it becomes a bigger problem. Dose adjustment based on those numbers, not on how you feel alone, since symptoms lag behind labs in both directions. Stick to the studied dose range (12.5 to 25mg/day) unless your prescriber has a specific, lab-driven reason to go outside it. Report visual symptoms immediately rather than waiting for the next scheduled follow-up. Source through a licensed prescriber and a compounding pharmacy with real oversight, not a research-chemical vendor with no prescription requirement and no quality documentation. If you're still deciding whether this approach makes sense for you at all, is enclomiphene worth it and enclomiphene pros and cons cover the tradeoffs against TRT in more depth, and enclomiphene before and after and enclomiphene reviews show what real users report at these dose levels, useful context alongside the toxicity data here.
Frequently asked questions
What are the first signs of taking too much enclomiphene?
The earliest overdose signs tend to be exaggerated versions of normal side effects: visual disturbances (blurring, light sensitivity), worsened headache, mood swings, and hot flashes. These reflect an estradiol and LH/FSH overshoot rather than organ damage. Visual symptoms are the one to treat seriously and report to a provider immediately, since clomiphene-class drugs list them as a reason to stop the medication [3].
Has anyone died from an enclomiphene overdose?
No published case of a fatal enclomiphene overdose exists in the medical literature as of this writing. Clinical trials tested doses up to 25mg/day for months without lethal or organ-threatening events reported [1]. That said, absence of published fatal cases isn't the same as a proven safe ceiling at any dose; extreme overdoses haven't been formally studied.
Is enclomiphene safer than testosterone replacement therapy?
They carry different risk profiles, not a simple safer/riskier ranking. TRT raises hematocrit and cardiovascular risk over time and reliably suppresses sperm production and testicular size. Enclomiphene tends to preserve fertility signaling and testicular size but carries its own risks (visual symptoms, mood changes, estradiol overshoot). Choose based on your fertility goals and risk tolerance, ideally with a prescriber.
What is the maximum safe dose of enclomiphene?
Clinical trials studied doses up to 25mg/day in the Androxal program, and most prescribers today stay within 12.5 to 25mg/day [1]. There's no FDA-approved label defining a hard maximum since enclomiphene isn't FDA-approved as a standalone drug. Going meaningfully above the studied range isn't supported by evidence of added benefit and raises side effect risk without a known safety ceiling.
Does enclomiphene overdose affect fertility differently than a normal dose?
There's no published data specifically on fertility effects of enclomiphene overdose. At normal doses, enclomiphene raises LH and FSH, which supports sperm production rather than suppressing it. At very high doses, the estradiol overshoot and hormonal disruption could theoretically impair the same feedback loop, but this isn't something formally studied; it's a reasonable mechanistic concern, not a documented finding.
Why isn't there an FDA label with an overdose section for enclomiphene?
Enclomiphene, developed as Androxal by Repros Therapeutics, completed Phase 3 trials but was never approved by the FDA, so no official label exists [1]. Everything prescribed today is compounded under physician prescription rather than sold as an FDA-approved commercial drug, which is why dosing and overdose guidance come from trial data and clinical judgment instead of a standardized label.
What should I do if I accidentally took a double dose?
Call your prescribing provider to report it; a single accidental double dose within the 12.5 to 25mg/day range is unlikely to cause serious harm based on published trial dosing [1]. Watch for visual changes, severe headache, or mood symptoms. If those appear, or if you took significantly more than double, call Poison Control at 1-800-222-1222 or seek emergency care.
Is compounded enclomiphene less safe than an FDA-approved drug?
Compounded drugs aren't independently verified for safety or effectiveness by the FDA, which states it "does not verify the safety, or effectiveness, of compounded drugs" [5]. This doesn't mean compounded enclomiphene is unsafe, but it does mean the pharmacy's quality standards matter more than they would with a mass-manufactured, FDA-approved pill. Choosing a reputable, physician-supervised source reduces this risk.
Can enclomiphene cause blood clots at high doses?
Clomiphene citrate's FDA label describes an association between the drug class and venous thromboembolism risk in some patients, though it's not framed as a common overdose-specific event [3]. Since enclomiphene shares clomiphene's estrogen-receptor-modulating mechanism, anyone with a personal or family history of blood clots should discuss this risk with a prescriber before starting, at any dose.
How is enclomiphene different from clomiphene in terms of toxicity?
Clomiphene citrate contains both enclomiphene and zuclomiphene isomers, while enclomiphene products isolate just the trans-isomer [4]. Zuclomiphene has a longer half-life and is suspected to contribute more to estrogen-related side effects. There's no head-to-head human toxicity data proving enclomiphene alone is safer at overdose levels; the rationale is sound pharmacology, not confirmed comparative safety outcomes.
What labs should be monitored to avoid enclomiphene toxicity?
Baseline and follow-up labs should include total and free testosterone, LH, FSH, estradiol, a complete blood count (to watch hematocrit), and a lipid panel. Follow-up around 6 to 12 weeks after starting or adjusting dose catches an estradiol or testosterone overshoot before it becomes symptomatic, which is a more reliable safety check than symptoms alone.
Who should not take enclomiphene at all?
Men with a personal or family history of blood clots, active liver disease, a history of pituitary or hypothalamic tumors, or pre-existing visual field problems should discuss these specifically with a prescriber before starting, since enclomiphene's mechanism and side effect profile interact with each of these conditions. This is a prescription decision, not a self-directed one.
Sources
- ClinicalTrials.gov, Repros Therapeutics Androxal Phase 3 trial record: Enclomiphene (Androxal) was studied at doses including 12.5mg and 25mg/day in Phase 3 trials for secondary hypogonadism and did not reach FDA approval
- PubMed, clomiphene citrate use in male infertility review: Clomiphene citrate has decades of off-label use in men at doses of roughly 50mg/day without a common pattern of acute lethal toxicity
- FDA, Clomiphene Citrate prescribing information (label): Clomiphene citrate's FDA label describes limited overdose experience, visual symptoms, and a class-level thromboembolism association
- PubMed, enclomiphene vs zuclomiphene pharmacology review: Clomiphene citrate is a mixture of the enclomiphene (trans) and zuclomiphene (cis) isomers with differing half-lives and receptor activity
- FDA, Compounding and the FDA: Questions and Answers: The FDA does not verify the safety or effectiveness of compounded drugs